275 related articles for article (PubMed ID: 15631545)
1. Cinacalcet hydrochloride.
Barman Balfour JA; Scott LJ
Drugs; 2005; 65(2):271-81. PubMed ID: 15631545
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
Nakanishi S; Fukagawa M
Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with cinacalcet HCl.
Ureña Torres P
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V27-33. PubMed ID: 15284357
[TBL] [Abstract][Full Text] [Related]
9. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
Henley C; Colloton M; Cattley RC; Shatzen E; Towler DA; Lacey D; Martin D
Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
11. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.
de Francisco AL
Expert Opin Pharmacother; 2005 Mar; 6(3):441-52. PubMed ID: 15794735
[TBL] [Abstract][Full Text] [Related]
13. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D
Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
Quarles LD
Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947
[TBL] [Abstract][Full Text] [Related]
15. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.
Quarles LD; Sherrard DJ; Adler S; Rosansky SJ; McCary LC; Liu W; Turner SA; Bushinsky DA
J Am Soc Nephrol; 2003 Mar; 14(3):575-83. PubMed ID: 12595492
[TBL] [Abstract][Full Text] [Related]
16. Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism.
Yajima A; Akizawa T; Tsukamoto Y; Kurihara S; Ito A;
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S38-43. PubMed ID: 19032526
[TBL] [Abstract][Full Text] [Related]
17. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.
Moe SM; Chertow GM; Coburn JW; Quarles LD; Goodman WG; Block GA; Drüeke TB; Cunningham J; Sherrard DJ; McCary LC; Olson KA; Turner SA; Martin KJ
Kidney Int; 2005 Feb; 67(2):760-71. PubMed ID: 15673327
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.
Charytan C; Coburn JW; Chonchol M; Herman J; Lien YH; Liu W; Klassen PS; McCary LC; Pichette V
Am J Kidney Dis; 2005 Jul; 46(1):58-67. PubMed ID: 15983958
[TBL] [Abstract][Full Text] [Related]
19. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.
Cunningham J; Danese M; Olson K; Klassen P; Chertow GM
Kidney Int; 2005 Oct; 68(4):1793-800. PubMed ID: 16164656
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
Fishbane S; Shapiro WB; Corry DB; Vicks SL; Roppolo M; Rappaport K; Ling X; Goodman WG; Turner S; Charytan C
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1718-25. PubMed ID: 18945995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]